Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 99.32% is in line with its 5-year average of 92.57%, near the high end of its 5-year range (16.36%–106.34%).
31.87% above its 12-month average of 75.32%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 71.59%.
GROSS MARGIN
99.32%
GROSS MARGIN AVG TTM
75.32%
GROSS MARGIN AVG 3Y
87.91%
GROSS MARGIN AVG 5Y
92.57%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+31.87%
CURRENT VS 3Y AVG
+12.98%
CURRENT VS 5Y AVG
+7.29%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
36.91%
median of 666 covered companies
CURRENT VS SECTOR MEDIAN
+169.09%
vs the sector median at left
Orchestra BioMed Holdings, Inc.
Market Cap
$354.49M
Gross Margin
99.32%
TTM Avg
75.32%
3Y Avg
87.91%
5Y Avg
92.57%
Market Cap
$356.50M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$356.36M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$348.59M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$365.97M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$374.07M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $354.49M | 99.32% | 75.32% | 87.91% | 92.57% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $356.50M | 98.15% | 96.49% | 98.25% | 98.83% |
| Embecta Corp. (EMBC)vs › | $355.67M | 59.89% | 63.90% | 65.83% | 67.05% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.36M | 93.73% | 92.44% | 93.34% | 78.89% |
| Ocugen, Inc. (OCGN)vs › | $359.46M | 45.86% | 48.66% | 71.42% | -2398.51% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | 0.00% | 50.00% | 75.00% | 66.67% |
| Opus Genetics, Inc. (IRD)vs › | $365.97M | 99.87% | 100.00% | 100.00% | 83.33% |
| Agenus Inc. (AGEN)vs › | $342.30M | 29.63% | -10.58% | -43.61% | -33.41% |
| Canopy Growth Corporation (CGC)vs › | $374.07M | 25.47% | 27.02% | 15.55% | 5.84% |
| Cabaletta Bio, Inc. (CABA)vs › | $333.45M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
99.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 71.59% |
| 2026-03-31 | 16.36% |
| 2025-12-31 | 99.84% |
| 2025-09-30 | 94.31% |
| 2025-06-30 | 94.50% |
| 2025-03-31 | 94.93% |
| 2024-12-31 | 77.08% |
| 2024-09-30 | 93.11% |
| 2024-06-30 | 94.34% |
| 2024-03-31 | 82.58% |
| 2023-12-31 | 68.32% |
| 2023-09-30 | 90.21% |
| 2023-06-30 | 94.10% |
| 2023-03-31 | 96.22% |
| 2022-12-31 | 95.19% |
| 2022-09-30 | 95.18% |
| 2022-06-30 | 85.04% |
| 2022-03-31 | 95.15% |
| 2021-12-31 | 102.36% |
| 2021-09-30 | 96.70% |
| 2021-06-30 | 106.34% |
| 2021-03-31 | 97.34% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
